Pages that link to "Q46157298"
Jump to navigation
Jump to search
The following pages link to Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation (Q46157298):
Displaying 50 items.
- Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (Q24632951) (← links)
- Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences (Q26746062) (← links)
- Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics (Q26822796) (← links)
- Pharmacogenetics and anaesthesia: the value of genetic profiling (Q26859221) (← links)
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing (Q27008360) (← links)
- Planning for translational research in genomics (Q28750341) (← links)
- Genomics: Implications for anesthesia, perioperative care and outcomes (Q28752236) (← links)
- Warfarin genotyping with hybridization-induced aggregation on a poly(ethylene terephthalate) microdevice. (Q30275196) (← links)
- Towards precision medicine (Q30391847) (← links)
- Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting. (Q30612258) (← links)
- Established Venous Thromboembolism Therapies: Heparin, Low Molecular Weight Heparins, and Vitamin K Antagonists, with a Discussion of Heparin-Induced Thrombocytopenia (Q33392669) (← links)
- Integration of genetic, clinical, and INR data to refine warfarin dosing (Q33550741) (← links)
- Warfarin pharmacogenomics (Q33561482) (← links)
- Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. (Q33619422) (← links)
- Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosingTest Category: Pharmacogenomic (Treatment) (Q33704981) (← links)
- Debating clinical utility (Q33832923) (← links)
- Expectations, validity, and reality in pharmacogenetics (Q33926313) (← links)
- Individualized cost-effectiveness analysis (Q33963712) (← links)
- Implementing genotype-guided antithrombotic therapy (Q33990428) (← links)
- Genotype-based dosing algorithms for warfarin therapy: data review and recommendations (Q34065133) (← links)
- The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop (Q34113976) (← links)
- Cost-effectiveness analysis for clinicians (Q34148072) (← links)
- Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation (Q34321590) (← links)
- Emerging clinical applications in cardiovascular pharmacogenomics (Q34400491) (← links)
- The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes (Q34583285) (← links)
- Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US. (Q34680367) (← links)
- Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model (Q34834319) (← links)
- Genetic warfarin dosing: tables versus algorithms. (Q35021027) (← links)
- Cardiovascular pharmacogenomics and individualized drug therapy (Q35025518) (← links)
- Pharmacogenomics--how close/far are we to practising individualized medicine for children? (Q35135951) (← links)
- Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design (Q35218128) (← links)
- Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey (Q35604901) (← links)
- Pharmacogenetics of drug-metabolizing enzymes in US Hispanics (Q35661209) (← links)
- Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility. (Q35681121) (← links)
- Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran. (Q35683869) (← links)
- A formal risk-benefit framework for genomic tests: Facilitating the appropriate translation of genomics into clinical practice (Q35854145) (← links)
- Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature (Q35890606) (← links)
- Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others (Q35955515) (← links)
- Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record (Q35991881) (← links)
- Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin (Q36015458) (← links)
- Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes (Q36044022) (← links)
- Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial (Q36195396) (← links)
- Will comparative effectiveness research finally succeed? (Q36327454) (← links)
- Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group (Q36366330) (← links)
- Cost‐effectiveness of Telemetry for Hospitalized Patients With Low‐risk Chest Pain (Q36502502) (← links)
- Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice (Q36702588) (← links)
- The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone (Q36794572) (← links)
- Role of pharmacogenomics in the management of traditional and novel oral anticoagulants (Q36848449) (← links)
- Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing (Q36921008) (← links)
- Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US. (Q36940076) (← links)